Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KJ-103
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
Cancer Research UK & KisoJi Advance TROP2 Antibody into Clinic
Details : The collaboration aims to bring KisoJi's lead asset, KJ-103, into a first-in-human clinical trial. KJ-103 is a naked anti-TROP2 antibody using its proprietary antibody technology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2024
Lead Product(s) : KJ-103
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
